---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055656"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:03:24.389160+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q1 net loss $63.3M; RGX-202 selects pivotal dose; cash $380.5M

## Summary
- Net loss $63.3M ($1.38 diluted EPS) vs $66.7M ($1.53) YoY; revenue $15.6M, down from $19.1M.
- Cash, equivalents and marketable securities $380.5M (up from $314.1M), runway into 2026.
- RGX-202 Duchenne: pivotal dose DL2 selected; second patient showed 20.9% microdystrophin expression, 90% CK reduction.
- ABBV-RGX-314 DR: positive interim ALTITUDE data; end-of-Phase II meeting FDA Q1 2025; pivotal trial H1 2025.
- RGX-121 BLA filing on track for 2024 via accelerated approval; potential Priority Review Voucher.

## SEC filing metadata
- accession: 0000950170-24-055656
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000095017024055656/0000950170-24-055656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000095017024055656/rgnx-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055656
- JSON: https://secwatch.observer/filing/0000950170-24-055656.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055656.txt

## Key facts
- Earnings Releases
  REGENXBIO Inc. reported the first quarter ending March 31, 2024 results: revenue $15.6 million.
  - Period: the first quarter ending March 31, 2024
  - Revenue: $15.6 million
  - Result: reported results
  source text: and pre-funded warrants completed in March 2024, and was partially offset by cash used to fund operating activities during the first quarter of 2024. Revenues: Revenues were $15.6 million for the three months ended March 31, 2024, compared to $19.1 million for the three months ended March 31, 2023. The decrease was primarily attributable to non-recurring
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000095017024055656/0000950170-24-055656-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.